



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 8 Mei 2018 (#14)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov).

**Confirm your intent to apply ASAP, but not later than 30 days before the submission date.**

**Contact: RGMO Pre-Awards [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)**

### Important Notices:

- Transition from Inclusion Management System to New Human Subjects System (HSS) as of June 9, 2018 ([NOT-OD-18-179](#))

### 1. Investigation of the Transmission of Kaposi Sarcoma-associated Herpesvirus (KSHV)(Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-CA-18-013](#)

**Type:** R01

**Application Due Date:** August 16, 2018. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of the funding opportunity announcement (FOA) is to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and risk factors for infection to inform efforts to prevent KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of developing HIV. This program covers two parallel FOAs of identical scientific scope. This FOA solicits applications for well-developed research projects using the NIH R01 funding mechanism. The companion FOA, RFA-CA-18-014, is a parallel announcement for exploratory/developmental projects using the NIH R21 mechanism.

**Budget:** NCI intends to commit an estimated total of \$3,000,000 to fund 4-6 awards. Application budgets should reflect the actual needs of the proposed project. Application budgets may not exceed \$500,000 direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

### 2. Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (KSHV) (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-CA-18-014](#)

**Type:** R21

**Application Due Date:** August 16, 2018. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of the funding opportunity announcement (FOA) is to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus (KSHV), also called human herpesvirus-8 (HHV-8); the biology of the initial steps of infection; and risk factors for infection to inform efforts to prevent KSHV transmission and thus prevent Kaposi sarcoma (KS), KSHV-associated multicentric Castleman disease (MCD), primary effusion lymphoma (PEL), and other KSHV-induced diseases in populations living with HIV or at high risk of developing HIV. This program covers two parallel FOAs of identical scientific scope. This FOA solicits applications for exploratory/developmental projects using the NIH R21 mechanism. The companion FOA, RFA-CA-18-013, is a parallel announcement for well-developed research projects using the NIH R01 funding mechanism.

**Budget:** NCI intends to commit an estimated total of \$1,500,000 to fund 4-6 awards. Direct costs are limited to \$275,000 over a two-year period, with no more than 200,000 in direct costs allowed in any single year. Application budgets should reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

### 3. Understanding Skeletal Effects of Type 1 Diabetes (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [RFA-DK-18-002](#)

**Type:** R01

**Application Due Date:** December 6, 2018. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) invites applications for studies to understand the effects of type 1 diabetes (T1D) on bone mass and quality and/or fracture risk. Researchers may propose investigations in newly recruited subjects or using subjects and/or samples from ongoing clinical studies of individuals with for T1D.

**Budget:** NIDDK intends to commit \$1,500,000 in FY 2019 to fund 3-4 awards. The number of awards is contingent upon availability of funds and the submission of a sufficient number of meritorious applications. Application direct cost budgets are limited to \$400,000 per year. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

#### 4. International Research Collaboration on Drug Abuse and Addiction Research (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-773\)](#)

**Type:** R01

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) encourages collaborative research applications on drug abuse and addiction that:

- Take advantage of unusual opportunities that exist outside the United States to access talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery
- Describe how the research will significantly advance U.S. health sciences
- Demonstrate specific relevance to the NIDA mission and objectives. To determine whether your research plan is relevant to the NIDA mission and objectives, review the NIDA Strategic Plan (<https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan>). Where feasible, applications should address NIDA's international scientific priority areas (<https://www.drugabuse.gov/international/research-priorities>)

- Include an investigator from a U.S. institution and a non-U.S. citizen partner living and working in another country.

**Budget:** The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

#### 5. Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Use Disorders (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-774\)](#)

**Type:** R34

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches, in addition to usual trial preparation activities.

**Budget:** The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Direct costs are limited to \$450,000 over the 3-year project period, with no more than \$225,000 in direct costs allowed in any single year. The total project period for an application submitted may not exceed three years.

#### 6. Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-775\)](#)

**Type:** R34

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) for R34 applications seeks to support: (a) pilot and/or feasibility testing of innovative new, revised, or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to misuse or problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving, prevent suicide attempts (nonfatal and fatal), and the drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings; and, (b) pre-trial feasibility and acceptability testing for prevention services and systems research. It is expected that research conducted via this mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale drug or alcohol abuse prevention and/or drug- or alcohol-related HIV prevention intervention studies. This FOA does not support applications for which the sole focus is development of intervention protocols, manuals, or the standardization of protocols. Any intervention development work must be imbedded within a pilot/feasibility study. Of particular interest is prevention research that addresses current public health priorities and priority settings and systems.

**Budget:** The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Applicants may request direct costs of up to \$450,000 for three years. Although variations from year to year are permissible, in no case may any year be more than \$225,000 in direct costs, and total direct costs for the entire project period may not exceed \$450,000. The maximum project period is 3 years.

#### 7. Maternal Nutrition and Pre-pregnancy Obesity: Effects on Mothers, Infants and Children (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-776\)](#)

**Type:** R01

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) encourages applications to improve health outcomes for women, infants and children, by stimulating interdisciplinary research focused on maternal nutrition and pre-pregnancy obesity. Maternal health significantly impacts not only the mother but also the intrauterine environment, and subsequently fetal development and the health of the newborn.

**Budget:** The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period for an application submitted in response to this funding opportunity may not exceed 5 years.

## 8. Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-18-780\)](#)

**Type:** R34

**Application Due Date:** [Standard AIDS dates](#). Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention, treatment or services research. For the purposes of this FOA, "intervention" may include behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches that prevent the acquisition and transmission of HIV infection, or improve clinical outcomes for persons who are HIV infected.

**Budget:** The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Direct costs are limited to \$450,000 over a three-year period, with no more than \$225,000 direct costs allowed in any single year. The maximum period is 3 years.

## 9. Novel Genomic Technology Development (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-18-777\)](#)

**Type:** R01

**Application Due Date:** October 2, 2018; October 2, 2019; October 2, 2020 and **Aids Dates** January 7, 2019; January 7, 2020; January 7, 2021  
Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) seeks grant applications to catalyze major advances in genomics through technology development (beyond developing nucleic acid sequencing technologies). The goal is to provide a mechanism for support of very novel and high impact work from across this gamut of genomics technology development. This initiative seeks to support technologies that will have a major impact in the next five to seven years.

**Budget:** The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. An applicant may request direct costs of up to \$700,000 per year. The scope of the proposed project should determine the project period. The maximum project period is 4 years.

## 10. Novel Genomic Technology Development (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PAR-18-778\)](#)

**Type:** R21

**Application Due Date:** October 2, 2018; October 2, 2019; October 2, 2020 and **Aids dates** January 7, 2019; January 7, 2020; January 7, 2021  
Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) encourages grant applications to catalyze major advances in genomics through technology development (beyond developing novel nucleic acid sequencing technologies). The goal is to provide a mechanism for support of very novel and high impact work from across this gamut of genomics technology development. This initiative seeks to support technologies that will have a major impact in the next five to seven years.

**Budget:** The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. An applicant may request direct costs of up to \$200,000 per year and no more than \$400,000 for the entire budget period. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University  
5<sup>th</sup> Floor, Teaching Block, Tygerberg Campus. • Enquiries: [Dr Christa Coetsee](#) • Tel: 9838 • Email: [cde.vries@sun.ac.za](mailto:cde.vries@sun.ac.za)